| Title |
Delayed Visual Improvement in Neuromyelitis Optica Spectrum Disorder With Severe Optic Atrophy |
| Creator |
Joshua Ong, MD, Peter Mortensen, MD, Subahari Raviskanthan, MBBS, Mohammad Pakravan, MD, Chaow Charoenkijkajorn, MD, Pamela Davila-Siliezar, MD, Noor A. Laylani, MD, Andrew G. Lee, MD |
| Affiliation |
Michigan Medicine (JO), University of Michigan, Ann Arbor, Michigan; Department of Ophthalmology (PM, SR, MP, CC, PD-S, NAL, AGL), Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas; Departments of Neurology (AGL) and Ophthalmology (AGL), Baylor College of Medicine, Houston, Texas; The Houston Methodist Research Institute (AGL), Houston Methodist Hospital, Houston, Texas; Departments of Ophthalmology, Neurology, and Neurosurgery (AGL), Weill Cornell Medicine, New York, New York; Department of Ophthalmology (AGL), University of Texas Medical Branch, Galveston, Texas; University of Texas MD Anderson Cancer Center (AGL), Houston, Texas; Texas A and M College of Medicine (AGL), Bryan, Texas and Department of Ophthalmology (AGL), The University of Iowa Hospitals and Clinics, Iowa City, Iowa |
| Subject |
Humans; Magnetic Resonance Imaging; Neuromyelitis Optica / complications; Neuromyelitis Optica / diagnosis; Neuromyelitis Optica / physiopathology; Optic Atrophy / diagnosis; Optic Atrophy / etiology; Optic Atrophy / physiopathology; Vision Disorders / diagnosis; Vision Disorders / etiology; Vision Disorders / physiopathology; Visual Acuity / physiology |
| Date |
2024-09 |
| Date Digital |
2024-09 |
| References |
Zarei S, Eggert J, Franqui-Dominguez L, et al. Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico. Surg Neurol Int. 2018;9:242. Menon V, Saxena R, Misra R, Phuljhele S. Management of optic neuritis. Indian J Ophthalmol. 2011;59:117-122. Cree BAC, Bennett JL, Kim HJ, et al.; N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394:1352-1363. |
| Language |
eng |
| Format |
application/pdf |
| Type |
Text |
| Publication Type |
Journal Article |
| Source |
Journal of Neuro-Ophthalmology, September 2024, Volume 44, Issue 3 |
| Collection |
Neuro-Ophthalmology Virtual Education Library: Journal of Neuro-Ophthalmology Archives: https://novel.utah.edu/jno/ |
| Publisher |
Lippincott, Williams & Wilkins |
| Holding Institution |
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416 |
| Rights Management |
© North American Neuro-Ophthalmology Society |
| ARK |
ark:/87278/s63q0zms |
| Setname |
ehsl_novel_jno |
| ID |
2901273 |
| Reference URL |
https://collections.lib.utah.edu/ark:/87278/s63q0zms |
